Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annika Nelde

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Cancer Discovery|May 20, 2021
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with CancerTatjana Bilich, Malte Roerden, Yacine Maringer, et al.
Haematologica|August 26, 2017
Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8<sup>+</sup> cytotoxic T cellsFalk Heidenreich, Elke Rücker-Braun, Juliane S Walz, et al.
EMBO Reports|April 27, 2021
NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodiesTeresa R Wagner, Elena Ostertag, Philipp D Kaiser, et al.
Frontiers in Immunology|December 11, 2024
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patientsJonas S Heitmann, Susanne Jung, Marcel Wacker, et al.
Nature Communications|November 18, 2023
TOF<sub>IMS</sub> mass spectrometry-based immunopeptidomics refines tumor antigen identificationNaomi Hoenisch Gravel, Annika Nelde, Jens Bauer, et al.
Blood|December 12, 2018
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapyTatjana Bilich, Annika Nelde, Leon Bichmann, et al.
Nature|November 23, 2021
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunityJonas S Heitmann, Tatjana Bilich, Claudia Tandler, et al.
Nature Communications|October 27, 2022
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer, Natalie Köhler, Yacine Maringer, et al.
Blood Cancer Discovery|October 17, 2023
Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor CellsAnnika Nelde, Heiko Schuster, Jonas S Heitmann, et al.
The Lancet. Haematology|January 17, 2026
Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 studyJonas S Heitmann, Yacine Maringer, Susanne Jung, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Cancer Discovery|May 20, 2021
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with CancerTatjana Bilich, Malte Roerden, Yacine Maringer, et al.
Haematologica|August 26, 2017
Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8<sup>+</sup> cytotoxic T cellsFalk Heidenreich, Elke Rücker-Braun, Juliane S Walz, et al.
EMBO Reports|April 27, 2021
NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodiesTeresa R Wagner, Elena Ostertag, Philipp D Kaiser, et al.
Frontiers in Immunology|December 11, 2024
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patientsJonas S Heitmann, Susanne Jung, Marcel Wacker, et al.
Nature Communications|November 18, 2023
TOF<sub>IMS</sub> mass spectrometry-based immunopeptidomics refines tumor antigen identificationNaomi Hoenisch Gravel, Annika Nelde, Jens Bauer, et al.
Blood|December 12, 2018
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapyTatjana Bilich, Annika Nelde, Leon Bichmann, et al.
Nature|November 23, 2021
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunityJonas S Heitmann, Tatjana Bilich, Claudia Tandler, et al.
Nature Communications|October 27, 2022
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer, Natalie Köhler, Yacine Maringer, et al.
Blood Cancer Discovery|October 17, 2023
Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor CellsAnnika Nelde, Heiko Schuster, Jonas S Heitmann, et al.
The Lancet. Haematology|January 17, 2026
Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 studyJonas S Heitmann, Yacine Maringer, Susanne Jung, et al.
Pageof 6